Cryptococcal meningitis: epidemiology and therapeutic options

• Main Authors: Sloan DJ, Parris V
• Format: Article
• Language: English
• Published: Dove Medical Press 2014-05-01
• Series: Clinical Epidemiology
• Online Access: http://www.dovepress.com/cryptococcal-meningitis-epidemiology-and-therapeutic-options-a16814

Derek J Sloan, Victoria Parris Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK Abstract: Cryptococcal meningitis causes morbidity and mortality worldwide. The burden of disease is greatest in middle- and low-income countries with a high incidence of human immunodeficiency virus (HIV) infection. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at risk. Treatment of cryptococcal meningitis consists of three phases: induction, consolidation, and maintenance. Effective induction therapy requires potent fungicidal drugs (amphotericin B and flucytosine), which are often unavailable in low-resource, high-endemicity settings. As a consequence, mortality is unacceptably high. Wider access to effective treatment is urgently required to improve outcomes. For human immunodeficiency virus-infected patients, judicious management of asymptomatic cryptococcal antigenemia and appropriately timed introduction of antiretroviral therapy are important. Keywords: cryptococcosis, HIV, immunosuppression, antifungal therapy, immune reconstitution inflammatory syndrome, antiretroviral therapy